Trial intelligence / Profile preview

Neo-adjuvant Erbitux in Locally Advanced Oral/Oropharyngeal Cancer

NCT01440270Phase 2Completed

Sponsor
Shanghai Jiao Tong University School of Medicine
Start
Aug 2011
Primary completion
Oct 2014
Modality
Monoclonal Antibodies
Countries
1
01

Overview

A Phase 2 trial of KL-140 in oral cancer, oropharyngeal cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Aug 2011; status: completed.

02

Drugs

KL-140
03

Conditions

oral canceroropharyngeal cancer

Beyond the preview

Go deeper on NCT01440270.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01440270.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call